Crinetics 开始第3阶段 测试阿梅宁, 一种针对典型先天性肾上腺增生的口服药物 阻断ACTH受体。 Crinetics begins Phase 3 trial for atumelnant, an oral drug targeting classic congenital adrenal hyperplasia by blocking ACTH receptors.

CALM-CAH试验第3阶段已经启动,向第一位成年病人服用了Amelnant,这是典型先天性肾上腺增生(CAH)的一种调查性口服药。 Crinetics Pharmaceuticals has initiated its Phase 3 CALM-CAH trial, dosing the first adult patient with atumelnant, an investigational oral drug for classic congenital adrenal hyperplasia (CAH). 该试验测试了阿图梅伦南特通过阻断ACTH受体来降低多余的雄激素产生和正常化葡萄皮质激素水平的能力. The trial tests atumelnant’s ability to reduce excess androgen production and normalize glucocorticoid levels by blocking the ACTH receptor. 在第二阶段取得积极成果后,关键生物标志和临床迹象迅速改善。 It follows positive Phase 2 results showing rapid improvements in key biomarkers and clinical signs. 该药物已获得林业发展局孤儿药品指认,其结果可能支持今后批准作为一流治疗。 The drug has received FDA Orphan Drug Designation, and results may support future approval as a first-in-class treatment.